Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
geptanolimab
- Development stage
- Phase 2
- Lead developer
- Genor Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Geptanolimab is a fully humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1). It functions as an immune checkpoint inhibitor by blocking the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2), thereby enhancing T-cell mediated immune responses against tumor cells. Geptanolimab is being developed primarily for the treatment of various cancers, including relapsed or refractory peripheral T-cell lymphoma (PTCL), cervical cancer, primary mediastinal large B-cell lymphoma (PMBCL), non-Hodgkin's lymphoma, and other solid tumors. The drug has demonstrated promising efficacy and a manageable safety profile in clinical trials for these indications[1][2][3][4][5][6][7][8].
- Brand names
- Aibining
- Other names
- Genolimzumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on geptanolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on geptanolimab.